Publication: Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol
Issued Date
2021-06-30
Resource Type
ISSN
20446055
Other identifier(s)
2-s2.0-85109047034
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMJ Open. Vol.11, No.6 (2021)
Suggested Citation
Passara Jongkhajornpong, Pawin Numthavaj, Thunyarat Anothaisintawee, Kaevalin Lekhanont, Gareth Mckay, John Attia, Ammarin Thakkinstian Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol. BMJ Open. Vol.11, No.6 (2021). doi:10.1136/bmjopen-2020-048479 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78119
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol
Other Contributor(s)
Abstract
Introduction Dry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED. Methods and analysis The study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18-70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer's I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance. Ethics and dissemination The study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences. Trial registration number NCT04683796.